tldrdailynews.com logo

Merck's Cholesterol Drug Excels in Phase 3 Trials

1 min read
Source: Merck.com
Merck's Cholesterol Drug Excels in Phase 3 Trials
Photo: Merck.com
TL;DR

Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, potentially making it the first oral PCSK9 inhibitor if approved.

Topics:businesshealthcare#enlicitide#healthcare#hyperlipidemia#ldl-c-reduction#merck#phase-3-trials
Share this article
  1. Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia  Merck.com
  2. Merck & Co.'s oral PCSK9 inhibitor succeeds in dual Phase III trials  FirstWord Pharma
  3. Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials  Fierce Biotech
  4. Merck's cholesterol drug meets main goal in two studies  Reuters
  5. Merck's potential cholesterol pill succeeds in late-stage studies  Business Standard

Want the full story? Read the original reporting

Read on Merck.com